Mouhammed Amir Habra MD
Adrenal Disease, Diabetes, Osteoporosis & Bone Metabolism Medicine, Thyroid
Professor
Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Fax+1 302-628-8357
Dr. Habra is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am an oncologic endocrinologist at MD Anderson Cancer Center.
My clinical practice focuses on endocrine tumors and endocrine complications in cancer patients with special interest in adrenal and thyroid tumors.
Education & Training
Baylor College of MedicineFellowship, Endocrinology, Diabetes, and Metabolism, 2002 - 2005
University of Missouri-ColumbiaResidency, Internal Medicine, 1999 - 2002
University of Aleppo Faculty of MedicineClass of 1995
Certifications & Licensure
FL State Medical License 2021 - Present
GA State Medical License 2024 - 2027
TX State Medical License 2008 - 2027
AZ State Medical License 2024 - 2026
LA State Medical License 2024 - 2026
MS State Medical License 2024 - 2026
OK State Medical License 2020 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
- Join now to see all
Clinical Trials
- Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma Start of enrollment: 2018 Feb 26
- Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence Start of enrollment: 2018 Aug 20
- A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma Start of enrollment: 2023 Mar 23
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Phase 2 Study of Monotherapy with Pembrolizumab for Advanced Adrenocortical Carcinoma.Brenda Chahla, Bettzy Stephen, Juhee Song, Vania Balderrama-Brondani, Feyza Yaylaci
Journal of Immunotherapy and Precision Oncology. 2025-11-01 - 1 citationsA Computed Tomography-Based Score to Predict Survival in Patients With Adrenocortical Carcinoma: A Proof-of-Concept Study.Maxime Barat, Mohamed Eltaher, Ahmed W Moawad, Philippe Soyer, David Fuentes
Canadian Association of Radiologists Journal = Journal L'association Canadienne Des Radiologistes. 2025-11-01 - β-catenin functions as a molecular adapter for disordered cBAF interactions.Yuen San Chan, Qinyu Gao, Sarah A Robinson, Wenzhi Wang, Ruzena Filandrova
Molecular Cell. 2025-08-21
Press Mentions
Management of Adrenocortical CarcinomaApril 10th, 2019
Lenvatinib Shows Promise for Patients with Radioiodine-Refractory Thyroid CancerFebruary 12th, 2015
A Retrospective Cohort Analysis of the Efficacy of Adjuvant Radiotherapy After Primary Surgical Resection in Patients with Adrenocortical Carcinoma, "Beyond the Abstract," by Mouhammed Amir Habra, MDFebruary 28th, 2013- Join now to see all
Professional Memberships
- Fellow
- Fellow
- Member
- Member
Other Languages
- Arabic
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
